Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 69 clinical trials
CSL312 (Garadacimab) in the Prevention of Hereditary Angioedema Attacks

This is a multicenter, double-blind, randomized, placebo-controlled, parallel-arm study to investigate the efficacy and safety of subcutaneous administration of CSL312 (garadacimab) in the prophylactic treatment of hereditary angioedema

  • 0 views
  • 28 Feb, 2021
  • 10 locations
Efficacy and Safety of Lanadelumab (SHP643) in Japanese Participants With Hereditary Angioedema (HAE)

The purpose of this phase 3, open-label, multi-center study is to evaluate the safety and efficacy of lanadelumab in Japanese participants with HAE Type I or II.

angioedema
bilateral oophorectomy
c1 inhibitor (human)
  • 5 views
  • 25 Jan, 2021
  • 12 locations
featured
Hereditary Angioedema (HAE)

An open-label study to evaluate the long-term safety of daily oral BCX7353 in subjects with Type I and Type II hereditary angioedema.

angioedema
  • 22 views
  • 14 May, 2020
  • 1 location
FIRAZYR General Drug Use-Results Survey (Japan)

The objectives of this survey are to collect data to report the safety and efficacy of Firazyr (Icatibant acetate) in the post-marketing phase in participants diagnosed with Hereditary Angioedema (HAE).

angioedema
icatibant
  • 14 views
  • 26 Jan, 2021
  • 18 locations
Study to Evaluate the Real-world Effectiveness of Lanadelumab in Participants With Hereditary Angioedema (HAE)

This observational, prospective study aims to evaluate the real-world effectiveness of lanadelumab in participants with hereditary angioedema (HAE). Participant-reported attack diaries and patient-reported outcomes (PROs) as well as physician assessments at standard of care (SoC) visits will be used to describe HAE attack rates, treatment patterns, healthcare utilization and participant …

angioedema
  • 76 views
  • 26 Jan, 2021
  • 31 locations
Patient Registry to Evaluate the Real-world Safety of Ruconest

This is a prospective, real-world, observational patient registry for patients with HAE who are receiving treatment with Ruconest for HAE.

c1 inhibitor (human)
ruconest
recombinant human c1 inhibitor
  • 64 views
  • 23 Jan, 2021
  • 1 location
Firazyr Patient Registry (Icatibant Outcome Survey - IOS)

The Icatibant Outcome Survey (IOS) is a prospective, observational disease registry designed to document the routine clinical outcomes over time in participants with angioedema treated with Firazyr (icatibant) and/or Cinryze (C1 inhibitor [human]) in countries where it is currently approved. The data collected will be used to evaluate the safety …

angioedema
cinryze
c1 inhibitor (human)
icatibant
  • 294 views
  • 25 Jan, 2021
  • 107 locations
C1 Inhibitor Registry in the Treatment of Hereditary Angioedema (HAE) Attacks

This is a non-interventional treatment Registry of Hereditary Angioedema (HAE) patients treated with C1 inhibitor, either plasma-derived (pdC1INH) or the recombinant human form (rhC1INH / Ruconest), to observe adverse events and insufficient efficacy, and to assess the immunological profile following single and repeated treatment with Ruconest.

angioedema
ruconest
c1 inhibitor (human)
  • 158 views
  • 25 Jan, 2021
  • 19 locations
CGRP Inhibition Autonomic Function and Migraine

The purpose of this clinical study is to better understand the function of the autonomic nervous system in patients with migraine. We aim to understand whether the autonomic functions change depending on the migraine status (i.e. whether they are between or during attacks) and whether the CGRP monoclonal antibody (mAb) …

  • 0 views
  • 26 Jan, 2021
  • 1 location